NCT02300298 - Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 24, 2014

Primary Completion Date

January 15, 2016

Study Completion Date

October 27, 2017

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Nintedanib

DRUG

Docetaxel

Trial Locations (6)

1199.90.81001 Boehringer Ingelheim Investigational Site, Chiba , Kashiwa

1199.90.81003 Boehringer Ingelheim Investigational Site, Kanagawa, Yokohama

1199.90.81007 Boehringer Ingelheim Investigational Site, Osaka, Osakasayama

1199.90.81006 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1199.90.81004 Boehringer Ingelheim Investigational Site, Shizuoka, Sunto-gun

1199.90.81002 Boehringer Ingelheim Investigational Site, Tokyo, Chuo